|Other Names||Melatonin receptor type 1A, Mel-1A-R, Mel1a receptor, MTNR1A|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP9283c was selected from the Center region of human MTNR1A. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||High affinity receptor for melatonin. Likely to mediates the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that inhibit adenylate cyclase activity.|
|Cellular Location||Cell membrane; Multi-pass membrane protein.|
|Tissue Location||Expressed in hypophyseal pars tuberalis and hypothalamic suprachiasmatic nuclei (SCN). Hippocampus|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
MTNR1A encodes one of two high affinity forms of a receptor for melatonin, the primary hormone secreted by the pineal gland. This receptor is a G-protein coupled, 7-transmembrane receptor that is responsible for melatonin effects on mammalian circadian rhythm and reproductive alterations affected by day length. The receptor is an integral membrane protein that is readily detectable and localized to two specific regions of the brain. The hypothalamic suprachiasmatic nucleus appears to be involved in circadian rhythm while the hypophysial pars tuberalis may be responsible for the reproductive effects of melatonin.
Adi,N., et.al., Med. Sci. Monit. 16 (2), BR61-BR67 (2010)Hill,S.M., et.al., Integr Cancer Ther 8 (4), 337-346 (2009)Lai,L., et.al., Breast Cancer Res. Treat. 118 (2), 293-305 (2009)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.